Patients treated with POTELIGEO? (mogamulizumab) with higher levels of abnormal T-cells in the blood reported higher quality of life, compared to vorinostat, new data analysis released today at the
Kyowa Kirin: New Data Analysis Shows Link between Blood Involvement and Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients afp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from afp.com Daily Mail and Mail on Sunday newspapers.
Patients treated with POTELIGEO®▼ (mogamulizumab) with higher levels of abnormal T-cells in the blood reported higher quality of life, compared to vorinostat, new data analysis released today at the European Hematology Association meeting1GALASHIELS, Scotland (BUSINESS WIRE) Kyowa Kirin International PLC (Kyowa Ki.
/PRNewswire/ Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced an agreement to jointly develop and commercialize KHK4083, which is.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis
February 18, 2021 GMT
TOKYO (BUSINESS WIRE) Feb 18, 2021
For Medical Media only. Kyowa Kirin Co., Ltd. (TSE: 4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, announces today that the Phase 2 study of investigational agent KHK4083 in patients with atopic dermatitis has met the primary endpoint.
KHK4083 is a potential first-in-class, anti-OX40 fully human monoclonal antibody for the treatment of autoimmune diseases, including atopic dermatitis. KHK4083 was first discovered by Kyowa Kirin, and is produced with the Company’s patented POTELLIGENT ® defucosylation technology to enhance its antibody dependent cellular cytotox